FDA Pauses Clozapine REMS Program Enforcement Due to High Volume of Patient Delays
The FDA has suspended a Clozapine REMS program's enforcement measures after numerous reports of patients suffering delays in getting the antipsychotic drug.
The FDA has suspended a Clozapine REMS program's enforcement measures after numerous reports of patients suffering delays in getting the antipsychotic drug.
The FDA warns that clozapine can cause potentially severe bowel problems which could result in injury, hospitalization or death.
A new study indicates psychotropic drugs cause genetic changes which leads to weight gain.
Amid concerns about the potential side effects of clozapine, federal health officials are requiring new warnings and patient monitoring for the schizophrenia medicine, indicating that there is growing evidence that…
A new study suggests that clozapine, a generic drug used for treatment of schizophrenia, may actually be safer than newer atypical antipsychotics, such as Seroquel. While the older and cheaper…